Evidence map›Paper›PMID 30397232›Full record

ArticleScientific reports2018

Aberrant DNA methylation of Tgfb1 in diabetic kidney mesangial cells.

Shigeyoshi Oba, Nobuhiro Ayuzawa, Mitsuhiro Nishimoto, Wakako Kawarazaki, Kohei Ueda, Daigoro Hirohama, Fumiko Kawakami-Mori, Tatsuo Shimosawa, Takeshi Marumo, Toshiro Fujita

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 26 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Unraveling the epigenetic landscape of glomerular cells in kidney disease.Journal of molecular medicine (Berlin, Germany) · 2021
    Review
  14. Review
  15. Epigenetics in kidney diseases.Advances in clinical chemistry · 2021
    Review
  16. Article
  17. Review
  18. Article
  19. Emerging strategies to disrupt the central TGF-β axis in kidney fibrosis.Translational research : the journal of laboratory and clinical medicine · 2019
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Shigeyoshi ObaDivision of Clinical Epigenetics, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. sooba-npr@umin.ac.jp.
Nobuhiro AyuzawaDivision of Clinical Epigenetics, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Mitsuhiro NishimotoDivision of Clinical Epigenetics, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0001-9542-847X
Wakako KawarazakiDivision of Clinical Epigenetics, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Kohei UedaDivision of Clinical Epigenetics, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Daigoro HirohamaDivision of Clinical Epigenetics, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Fumiko Kawakami-MoriDivision of Endocrinology, Mitsui Memorial Hospital, Tokyo, Japan.
Tatsuo ShimosawaDepartment of Clinical Laboratory, International University of Health and Welfare, School of Medicine, Mita Hospital IUHW, Tokyo, Japan.ORCID http://orcid.org/0000-0002-8742-5129
Takeshi MarumoDivision of Clinical Epigenetics, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan.
Toshiro FujitaDivision of Clinical Epigenetics, Research Center for Advanced Science and Technology, The University of Tokyo, Tokyo, Japan. Toshiro.FUJITA@rcast.u-tokyo.ac.jp.
The University of Tokyo · JPMita Hospital · JPMitsui Memorial Hospital · JPThe Graduate University for Advanced Studies, SOKENDAI · JPTokyo Fuji University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Epigenetic modulation may underlie the progression of diabetic nephropathy (DN). Involvement of TGFB1 in mesangial fibrosis of DN led us to hypothesize that Tgfb1 DNA demethylation contributes to progression of DN. In primary mesangial cells from diabetic (db/db) mouse kidneys, demethylation of Tgfb1 DNA and upregulation of Tgfb1 mRNA progressed simultaneously. USF1 binding site in Tgfb1 promoter region were demethylated, and binding of USF1 increased, with decreased binding of DNMT1 in db/db compared with control. Given downregulation of Tgfb1 expression by folic acid, antioxidant Tempol reversed DNA demethylation, with increased and decreased recruitment of DNMT1 and USF1 to the promoter, resulting in decreased Tgfb1 expression in db/db mice. Addition of H

Indexed as

DNA MethylationAnimalsDiabetes Mellitus, ExperimentalDisease ProgressionFibrosisMaleMesangial CellsMiceMice, Inbred C57BLPromoter Regions, GeneticReactive Oxygen SpeciesRNA, MessengerTransforming Growth Factor beta1Up-RegulationReactive Oxygen SpeciesRNA, MessengerTgfb1 protein, mouseTransforming Growth Factor beta1

Identifiers

PMID30397232
PMCPMC6218490
OpenAlexW2899238419

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.